Cargando…

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study

PURPOSE: The objective of this study was to characterize the demographic and clinical profile of RRMS patients receiving fingolimod in Spain, and to evaluate drug effectiveness and safety in clinical practice. METHODS: This observational, retrospective, multicentre, nationwide study was performed at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barrero, Francisco, Mallada-Frechin, Javier, Martínez-Ginés, María Luisa, Marzo, María Eugenia, Meca-Lallana, Virginia, Izquierdo, Guillermo, Ara, José Ramón, Oreja-Guevara, Celia, Meca-Lallana, José, Forero, Lucía, Sánchez-Vera, Irene, Moreno, María José
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117743/ https://www.ncbi.nlm.nih.gov/pubmed/32240213 http://dx.doi.org/10.1371/journal.pone.0230846

Ejemplares similares

Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry
por: Meca-Lallana, J. E., et al.
Publicado: (2021)

Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
por: Sánchez-de la Rosa, Rainel, et al.
Publicado: (2015)

Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing–Remitting Multiple Sclerosis: Quantifying the Patient’s Perspective
por: Meca-Lallana, José, et al.
Publicado: (2020)

Family Planning in Fertile-Age Patients With Multiple Sclerosis (MS) (ConPlanEM Study): Delphi Consensus Statements
por: Oreja-Guevara, Celia, et al.
Publicado: (2023)

Cognitive Dysfunctions and Assessments in Multiple Sclerosis
por: Oreja-Guevara, Celia, et al.
Publicado: (2019)

Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients’ Perspective: An Observational Cross-Sectional Study
por: Meca-Lallana, José E., et al.
Publicado: (2022)

Spasticity in multiple sclerosis and role of glatiramer acetate treatment
por: Meca-Lallana, Jose Eustasio, et al.
Publicado: (2015)

Disability and Fatigue in Multiple Sclerosis: Can Rehabilitation Improve Them through a Structured Retraining Program?
por: Arriaza, María José, et al.
Publicado: (2022)

Quantifying the patient´s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire
por: Meca-Lallana, José E., et al.
Publicado: (2021)

Consensus on early detection of disease progression in patients with multiple sclerosis
por: Meca-Lallana, José E., et al.
Publicado: (2022)

Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder
por: Meca-Lallana, Jose E, et al.
Publicado: (2021)

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study
por: Izquierdo, Guillermo, et al.
Publicado: (2017)

COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies
por: Meca-Lallana, Virginia, et al.
Publicado: (2020)

Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
por: Aguirre, Clara, et al.
Publicado: (2020)

Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder
por: Lopez-Soley, Elisabet, et al.
Publicado: (2022)

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
por: Gajofatto, Alberto, et al.
Publicado: (2015)

Use of Fingolimod in the Management of Relapsing–Remitting Multiple Sclerosis: Experience from Latin America
por: Correale, Jorge, et al.
Publicado: (2015)

Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod
por: Gasperini, Claudio, et al.
Publicado: (2013)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
por: Yavari, Fatemeh, et al.
Publicado: (2021)

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
por: Spelman, Timothy, et al.
Publicado: (2021)

XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)
por: Fernández, Óscar, et al.
Publicado: (2023)

XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)
por: Fernández, Óscar, et al.
Publicado: (2023)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

Cardiac repolarization during fingolimod treatment in patients with relapsing–remitting multiple sclerosis
por: Laiho, Aapo, et al.
Publicado: (2018)

Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran
por: Ouspid, Elham, et al.
Publicado: (2018)

Alternate dosing of fingolimod in relapsing-remitting multiple sclerosis: A systematic review
por: Ghadiri, Fereshteh, et al.
Publicado: (2023)

Treatment with Natalizumab in Relapsing–Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism
por: Ramos-Cejudo, Jaime, et al.
Publicado: (2011)

Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
por: Comi, Giancarlo, et al.
Publicado: (2020)

Perception of stigma in patients with primary progressive multiple sclerosis
por: Pérez-Miralles, Francisco, et al.
Publicado: (2019)

Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
por: Meca-Lallana, José E., et al.
Publicado: (2023)

Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study
por: Hernández-Preciado, Martha Rocio, et al.
Publicado: (2022)

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
por: Oreja-Guevara, Celia, et al.
Publicado: (2012)

The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis
por: Derfuss, T, et al.
Publicado: (2020)

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021)

Establishment of a safety protocol for the administration of treatments in multiple sclerosis during the SARS-CoV-2 pandemic
por: Meca-Lallana, Virginia, et al.
Publicado: (2020)

Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS
por: Fernández-Velasco, José I., et al.
Publicado: (2021)

Real‐life long‐term effectiveness of fingolimod in Swiss patients with relapsing‐remitting multiple sclerosis
por: Zecca, C., et al.
Publicado: (2018)

Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
por: Grahl, S., et al.
Publicado: (2021)

Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
por: Doosti, Rozita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9oi0uvu4u8la0vlfs9vl0bdb3u